Clinical perspective of the COAST-study for unresectable Stage III NSCLC
In this MEDtalk Roy S. Herbst, Medical Oncologist answers questions about the COAST-study of patients with locally advanced, unresectable, stage III NSCLC with durmavumab alone or in combination with novel agents.